Hutchmed to divest its 45% equity interest in SHPL to GP Health Service Capital & Shanghai Pharma for approx. US$ 608 million: Hong Kong, Shanghai Friday, January 3, 2025, 13:00 H ...
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR ), today announced significant progress in ...
We also gained substantial knowledge of these oncogenic pathways, and the issues involved in addressing them. In contrast to traditional cytotoxin-based ADCs, we believe that our antibody-targeted ...
Section of Digestive Diseases and Nutrition, University of Illinois at Chicago and Chicago Veterans Administration Medical Center (West Side Division), Chicago, IL, USA Correspondence to: Dr G Hecht, ...
The drug candidate is a bicyclic peptide conjugate being developed based on bicyclic peptide technology. It acts by targeting nectin-4 linked to the cytotoxin monomethyl auristatin E (MMAE) by a ...
The drug candidate is a bicyclic peptide conjugate being developed based on bicyclic peptide technology. It acts by targeting nectin-4 linked to the cytotoxin monomethyl auristatin E (MMAE) by a ...
type III secretion apparatuses and cilia), secreted molecules (such as quorum signals and tracheal cytotoxin) and regulatory systems (such as two-component response regulator systems and AraC ...
1 Department of Cellular Neurophysiology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic (ASCR), Prague, Czechia 2 Second Faculty of Medicine, Charles University, Prague ...
1 Centro Multidisciplinario de Estudios en Biotecnología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico 2 School of Chemical Sciences, ...